NCT05417880 (VETA) is a Phase 3 clinical trial of Oral Hypoglycemic Agents,Oral in Diabetes Mellitus, sponsored by Scotmann Pharmaceuticals.

Who is sponsoring NCT05417880?

NCT05417880 is sponsored by Scotmann Pharmaceuticals.

What drugs are being tested in NCT05417880?

Interventions in NCT05417880: Oral Hypoglycemic Agents,Oral, Voreta, Voreta plus SunnyD PRO.

What condition does NCT05417880 study?

NCT05417880 studies Diabetes Mellitus.

Is NCT05417880 still recruiting?

NCT05417880 is currently status unknown. Last updated 10 June 2022.

Last reviewed 2022-06-10 · How we verify

NCT05417880: VETA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin D, K2 Plus Empagliflozin Combination in Type Two Diabetes Mellitus

Status unknown Phase 3 Last updated 10 June 2022

What this trial tests

Phase 3 trial testing Oral Hypoglycemic Agents,Oral in Diabetes Mellitus in 340 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
1 February 2023

1 June 2023

Quick facts

Lead sponsor	Scotmann Pharmaceuticals
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	340
Start date	1 August 2022
Primary completion	1 February 2023
Estimated completion	1 June 2023
Sites	1 location across Pakistan

Drugs / interventions tested

Oral Hypoglycemic Agents,Oral — full drug profile →
Voreta — full drug profile →
Voreta plus SunnyD PRO — full drug profile →

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

Scotmann Pharmaceuticals — full company profile →

Who can join

Adults 40 to 60, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

HbA1c
Time frame: 3 months
Mean change in HbA1c levels in % from baseline to end of study at 3 months
Fasting Blood Sugar (FBS)
Time frame: 3 months
Mean change in Fasting blood sugar ( serum levels of Glucose in mg/dL after 6-8 hours of fasting) from baseline to end of study at 3 months
Random Blood Sugar (RBS)
Time frame: 3 months
Mean change in Random blood sugar from baseline to end of study at 3 months. ( A random glucose test is one method for measuring the amount of glucose or sugar circulating in a person's blood. Doctors perform this test and use the result to determine whether a person is likely to have diabetes)
Hypotension
Time frame: 3 months
Number of times ( frequency) the patient experienced low blood pressure during the defined study time frame
Dehydration
Time frame: 3 months
Number of times (frequency) the patient felt dehydrated during the defined time frame
Urinary Tract Infection
Time frame: 3 months
Incidence of clinically diagnosed or patient's self-reported Urinary Tract Infections

Sponsor's own description

The main purpose of the VETA trial is to verify the potential beneficial effects of the combination of micronutrients namely Vitamin D3 and K2 in combination with oral antihyperglycemic Empagliflozin in Diabetes Mellitus

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other Scotmann Pharmaceuticals trials

Trials by the same sponsor.

NCT05104970 — Comparative Pharmacokinetics of Two Different Oral Delivery Systems of Cholecalciferol · Phase 2 · unknown
NCT05088928 — Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05417880 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scotmann Pharmaceuticals
Last refreshed: 10 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05417880.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing